CAS: 53324-38-2; 4-Bromo-3-Nitroaniline

上下游产品

CAS号99-09-2 间硝基苯胺 | CAS号106-40-1 对溴苯胺 | CAS号20244-61-5 2,4,4,6-四溴-2,5-环己二烯酮 | CAS号584-48-5 1-溴-2,4-二硝基苯 | CAS号122-28-1 3'-硝基乙酰苯胺 | CAS号40101-31-3 N-(4-溴苯基)邻苯二甲酰亚胺 | CAS号7726-95-6 溴素 | CAS号64-19-7 冰醋酸 | CAS号7664-93-9 硫酸 | CAS号7697-37-2 硝酸 | CAS号51686-78-3 2,4-二溴硝基苯 | CAS号82-71-3 2,4,6-三硝基间苯二酚,收敛酸 | CAS号19230-27-4 1,3-二溴-2-氯苯 | CAS号608-30-0 2,6-二溴苯胺 | CAS号13402-32-9 2,6-二溴硝基苯 | CAS号13506-78-0 1,3-二溴-2,4,6-三硝基苯 | CAS号1630-08-6 2,4-Diamino-1,3... | CAS号713512-18-6 1-溴-4-碘-2-硝基苯 | CAS号608-21-9 1,2,3-三溴苯 | CAS号62406-72-8 2,4,6-Tribromo-...

📜间硝基苯胺置于4O4S(2-)*8Na(1+)*2H2O2*nacl,溶剂黄146,Potassium Bromide体系中,化学反应 4.0H,以83%的收率获得产物4-溴-3-硝基苯胺
参考文献:硫酸钠-过氧化氢-氯化钠加合物:硫化物氧化成亚砜和砜的氧化溴化,碘化和温度依赖性氧化的选择性方案†
标题:硫酸钠-过氧化氢-氯化钠加合物:硫化物氧化成亚砜和砜的氧化溴化,碘化和温度依赖性氧化的选择性方案†
摘要:已经开发了在温和条件下使用包封的过氧化氢作为氧化剂对未保护的芳族伯胺进行区域选择性溴化和碘化的方法,其中溴化钾(kbr)和碘化钾(ki)分别用作溴化剂和碘化剂.加合物不仅显示出对位或邻位的区域选择性-异构体,但对单溴化反应也具有显着的化学选择性.还研究了将硫化物选择性氧化为亚砜和砜的方法,获得了所需产品的非常好或优异的收率.发现乙酸是这些反应的选择溶剂.这种简单的方法代表了苯胺的氧化卤化和硫化物氧化为亚砜和砜的生态友好的替代途径.
DOI:10.1039/c8Nj06038J

专利信息

专利号:US-8178559-B2
优先权日:2004-12-30
标 题:Organic compounds
发明人：BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI
权利人:BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.